(Q35681948)

9 August 2017

Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma (English)

1 reference

metastatic renal cell carcinoma

9 August 2017

1 reference

1 reference

G Groenewegen

1

1 reference

9 August 2017

M Walraven

2

1 reference

9 August 2017

J Vermaat

3

1 reference

9 August 2017

B de Gast

4

1 reference

9 August 2017

E Witteveen

5

1 reference

9 August 2017

R Giles

6

1 reference

9 August 2017

J Haanen

7

1 reference

9 August 2017

E Voest

8

1 reference

9 August 2017

language of work or name

English

0 references

publication date

3 January 2012

1 reference

British Journal of Cancer

9 August 2017

1 reference

9 August 2017

106

1 reference

9 August 2017

2

1 reference

9 August 2017

284-289

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.515

9 August 2017

0 references

cites work

Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Immunotherapy for renal cell cancer in the era of targeted therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

The endothelin axis in cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Sorafenib in advanced clear-cell renal-cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Prognostic value of thrombocytosis in renal cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Interferon-alpha: regulatory effects on cell cycle and angiogenesis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Vascular endothelial growth factor: basic science and clinical progress

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

The endothelin axis: emerging role in cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Cancer immunotherapy: the interferon-alpha experience

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Platelet: transporter of vascular endothelial growth factor

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

27 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.515

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.515

Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.515

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.515

Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.515

Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.515

Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.515

Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3261664

Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma

25 September 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.515

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22215065

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Atrasentan treatment of pulmonary vascular disease in piglets with increased pulmonary blood flow

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22215065

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2011.515

1 reference

Dimensions Publication ID

9 August 2017

0 references

1 reference

9 August 2017

1 reference